Vera Therapeutics (VERA) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$1.20
- EPS estimate
- −$0.82
- EPS surprise
- −46.06%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 5, 2025
Vera Therapeutics' latest reported quarter in the table is Q2 2025, reported on August 5, 2025. The company lost $1.20 per share, a wider loss than the $0.82 estimate, for a 46.06% miss. The table shows no revenue and no revenue estimate. A year earlier, in Q2 2024, the loss was $0.62 per share, so the loss nearly doubled.
Vera has posted a loss in every one of the 18 quarters shown. Annual losses were $13.71 per share in 2021, driven by a $12.23 loss in Q1 2021, then $3.34 in 2022, $2.25 in 2023 and $2.75 in 2024. The first half of 2025 totals a loss of $2.01, about 70% larger than the $1.18 a year earlier. Losses widened in each of the last four quarters compared with the same quarter a year before. Against estimates, results came in worse than forecast 12 times and better 6 times over the 18 quarters.
The table holds no results after Q2 2025. In earlier years Vera reported Q3 between November 7 and November 10, and Q4 in late February or March. A newer report will show whether the per-share loss keeps widening and whether the company records revenue.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 5, 2025 | −$0.82 | −$1.20 | −46.06% | $0.00 | SEC |
| Q1 2025 | May 6, 2025 | −$0.74 | −$0.81 | −9.27% | $0.00 | SEC |
| Q4 2024 | Feb 26, 2025 | −$0.81 | −$0.72 | +11.35% | $0.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.64 | −$0.85 | −33.33% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.56 | −$0.62 | −10.71% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.53 | −$0.56 | −5.58% | $0.00 | SEC |
| Q4 2023 | Mar 20, 2024 | −$0.50 | −$0.54 | −6.99% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.52 | −$0.45 | +13.24% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.65 | −$0.46 | +29.60% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.57 | −$0.80 | −40.62% | $0.00 | SEC |
| Q4 2022 | Mar 28, 2023 | −$0.86 | −$1.17 | −35.31% | $0.00 | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.70 | −$0.91 | −30.02% | $0.00 | SEC |
| Q2 2022 | Aug 10, 2022 | −$0.68 | −$0.55 | +18.91% | $0.00 | SEC |
| Q1 2022 | May 16, 2022 | −$0.63 | −$0.71 | −12.11% | $0.00 | SEC |
| Q4 2021 | Mar 24, 2022 | −$0.45 | −$0.79 | −74.28% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.69 | −$0.36 | +47.58% | $0.00 | SEC |
| Q2 2021 | Aug 16, 2021 | −$0.39 | −$0.33 | +15.38% | $0.00 | SEC |
| Q1 2021 | Jun 24, 2021 | −$1.95 | −$12.23 | −528.79% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Vera Therapeutics (VERA) last report earnings?
Vera Therapeutics last reported on Aug 5, 2025, covering fiscal Q2 2025.
Did VERA beat earnings estimates?
No. Vera Therapeutics reported EPS of −$1.20 for Q2 2025 against a −$0.82 estimate — a 46.06% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.